Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases

Details for Australian Patent Application No. 2002333758 (hide)

Owner Novartis AG

Inventors Iwasaki, Genji; Altman, Eva; Hayakawa, Kenji

Agent Davies Collison Cave

Pub. Number AU-B-2002333758

PCT Number PCT/EP02/09661

PCT Pub. Number WO2003/020278

Priority 0121026.9 30.08.01 GB; 0121024.4 30.08.01 GB

Filing date 29 August 2002

Wipo publication date 18 March 2003

Acceptance publication date 19 January 2006

International Classifications

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

C07D 239/42 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 403/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

Event Publications

13 February 2003 Complete Application Filed

  Priority application(s): 0121026.9 30.08.01 GB; 0121024.4 30.08.01 GB

5 June 2003 Application Open to Public Inspection

  Published as AU-B-2002333758

19 January 2006 Application Accepted

  Published as AU-B-2002333758

18 May 2006 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002333759-METHODS FOR THE TREATMENT OF CHRONIC PAIN ANC COMPOSITIONS THEREFOR

2002333757-Use of annellated pyrrole compounds in the treatment of articular cartilage or subchondral bone degeneration